Sowmya Viswanathan, PhD

Background
Dr. Viswanathan is a Senior Scientist at UHN’s Krembil Research Institute and an Associate Professor at the University of Toronto's Institute of Biomedical Engineering and Division of Hematology. She previously worked in industry at Johnson & Johnson, developing regenerative medicine products, and later helped lead UHN’s Cell Therapy Program as Associate Director, supporting over 13 clinical trials and building expertise in cell manufacturing and regulatory science. She established her independent lab at UHN in 2015.
Leadership
Dr. Viswanathan’s work and leadership are internationally recognized– she is an elected VP of the North American Region for the International Society for Cell and Gene Therapy (ISCT) for 2026-2028; co-chair of their Signature Series on Artificial Intelligence, which will be held in Cambridge, MA in 2026, and is on the organization committee for ISCT's North American Regional Meeting to be held in Houston, TX in 2027. Dr. Viswanathan has been scientific chair of the MSC Committee at ISCT (2022-2026; co-chair from 2020-2022) and is the current co-chair of the Orthopedic & Musculoskeletal Therapies Committee at ISCT.
Dr. Viswanathan sits on the ISCT Board of Directors as VP, North America (2026-2028) and previously as an elected member (2020-2022). She served as Associate Editor of Cytotherapy, the official journal of ISCT for seven years (2018 – 2025). Additionally, Dr. Viswanathan sits on scientific advisory board for different cell therapy companies.
As a translational scientist, Dr. Viswanathan is a national regulatory and cell manufacturing consultant in leading policy and standards initiatives across Canada and internationally. She chaired the Cell Therapy Stakeholder Group engaging Health Canada on cell therapy related policy issues from 2015 to 2021. Dr. Viswanathan is a founding member and Manufacturing Committee lead within CellCAN, and previously served on CIHR’s Stem Cell Oversight Committee. She is the Chair of the highly reputed Mesenchymal Stromal Cell (MSC) Scientific Committee at the International Society for Cell and Gene Therapy from June 2022 to July 2026. She led the development of two international MSC nomenclature and characterization standardization through the International Standards Organization (ISO) TC276, the Standards Coordinating Body, and ISCT.
Research
View all of Dr. Sowmya Viswanathan’s work and research interests here: Research.
Publications
View all of Dr. Sowmya Viswanathan’s publications across PubMed, Scopus and ORCID, featuring work in Cell Stem Cell and Nature’s CMI. Explore a recent list of publications here: Publications.
Clinical Research
Dr. Viswanathan leads several clinical trials, working closely with orthopedic surgeons in the Division of Orthopedic Surgery at the Schroeder Arthritis Institute. She was co-PI of a MSC-OA trial (Use of Autologous Human Mesenchymal Stromal Cells (MSCs) for the Treatment of Knee Joint Osteoarthritis), ClinicalTrials.gov ID: NCT02351011; Health Canada Control No # 177258. See Chahal et al. for publication. This paper received The Arthritis Society Canada’s Top 10 Research Achievements in 2019.
She is also the Sponsor-PI on a currently recruiting cellular therapy trial in knee osteoarthritis patients, called ABLE OA (Autologous Bone Marrow or Lipoaspirate Evaluation against PRP in Knee and Shoulder OsteoArthritis Patients). This is a Health Canada authorized Phase II/III trial co-led with Dr. Chris Kim, to assess the efficacy of autologous cellular therapy preparations in modulating pain and symptoms in knee osteoarthritis patients. The study is also designed to collect information on the cellular therapy product and patient biomarkers to identify more responsive patients. ClinicalTrials.gov ID: NCT05517434. This study is a flagship of the Schroeder Arthritis Advanced Therapeutics Centre (SAATC) which Dr. Viswanathan co-directs. Under this center, a clinical cohort study called LEAP IN BIO (Longitudinal Evaluation of Arthritis Patients with Injectable Biologics), 400 knee and shoulder OA patient is also underway (REB# 21-6226). This study will similarly evaluate baseline immune profiles to identify responders.
Dr. Viswanathan is a co-PI with Dr. Lauren King on an Arthritis Society Canada (TAS) Strategic Operating Grant–funded study, MELO (Melatonin for Symptomatic Knee Osteoarthritis: A Randomized Controlled Trial). This trial evaluates the safety and efficacy of melatonin as a novel therapeutic strategy for symptomatic knee osteoarthritis patients, with the goal of improving pain management, physical function, and patient quality of life through a well‑tolerated intervention.
EDI Statement
At the Viswanathan lab, we respect everyone and value the diversity in our community, including but not limited to the four designated groups as established by the employment equity act; women, indigenous peoples, persons with disabilities and racialized minorities. Also, we make sure that all students and employees have the same opportunity to participate in various projects and reach their full potential.